Inflammation

Oculus Innovative Sciences Announces Results From Anti-Inflammatory Study Using Microcyn Technology

Published in Health Business Week, July 13th, 2007

Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced that International Immunopharmacology has published results from a company-sponsored study evaluating the impact of the Microcyn(R) Technology, a super-oxidized oxychlorine compound, on degranulation and cytokine release in mast cells. A reprint of the study can be viewed online: http://www.oculusis.com/articles/mastcells.pdf.

It is well established that studies on mast cell physiology are useful in identifying possible therapeutic targets for allergic/inflammatory diseases. Inflammation, often associated with certain open wounds, can delay wound healing if not controlled.

The study explored...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Business Week

Source: Health Business Week (2007-07-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry